AR117640A1 - Compuestos de 2,6-diaminopiridina como inhibidores de khk - Google Patents
Compuestos de 2,6-diaminopiridina como inhibidores de khkInfo
- Publication number
- AR117640A1 AR117640A1 ARP190102434A ARP190102434A AR117640A1 AR 117640 A1 AR117640 A1 AR 117640A1 AR P190102434 A ARP190102434 A AR P190102434A AR P190102434 A ARP190102434 A AR P190102434A AR 117640 A1 AR117640 A1 AR 117640A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- khk
- inhibitors
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- VHNQIURBCCNWDN-UHFFFAOYSA-N pyridine-2,6-diamine Chemical class NC1=CC=CC(N)=N1 VHNQIURBCCNWDN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- PFNOWXFRAIHXMZ-WDEREUQCSA-N 2-[(3R)-1-[5-cyano-6-[(2S)-2-methylazetidin-1-yl]-4-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]acetic acid Chemical compound C(#N)C=1C(=CC(=NC=1N1[C@H](CC1)C)N1C[C@H](CC1)CC(=O)O)C(F)(F)F PFNOWXFRAIHXMZ-WDEREUQCSA-N 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Ácido 2-[(3R)-1-[5-ciano-6-[(2S)-2-metilazetidin-1-il]-4-(trifluorometil)-2-piridilo]pirrolidin-3-il]acético como inhibidores de KHK, una composición farmacéutica que lo comprende y su uso para el tratamiento de diabetes mellitus tipo 2, insuficiencia cardíaca, enfermedad renal diabética y esteato hepatitis no alcohólica. Reivindicación 1: Un compuesto de la fórmula (1), en donde n es 1 ó 2; o una sal farmacéuticamente aceptable de este. Reivindicación 6: El compuesto de acuerdo con la reivindicación 5, en donde el compuesto es: de fórmula (2), o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726520P | 2018-09-04 | 2018-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117640A1 true AR117640A1 (es) | 2021-08-18 |
Family
ID=67982138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102434A AR117640A1 (es) | 2018-09-04 | 2019-08-27 | Compuestos de 2,6-diaminopiridina como inhibidores de khk |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10781212B2 (es) |
| EP (1) | EP3846809B1 (es) |
| JP (1) | JP6813720B1 (es) |
| KR (1) | KR102365535B1 (es) |
| CN (1) | CN112601525B (es) |
| AR (1) | AR117640A1 (es) |
| AU (1) | AU2019334877B2 (es) |
| BR (1) | BR112021001881A2 (es) |
| CA (1) | CA3111725C (es) |
| CL (1) | CL2021000528A1 (es) |
| CO (1) | CO2021002768A2 (es) |
| CR (1) | CR20210085A (es) |
| DO (1) | DOP2021000027A (es) |
| EA (1) | EA202190302A1 (es) |
| EC (1) | ECSP21015267A (es) |
| IL (1) | IL280598B2 (es) |
| JO (1) | JOP20210039A1 (es) |
| MA (1) | MA53547A (es) |
| MX (1) | MX2021002472A (es) |
| PE (1) | PE20211595A1 (es) |
| PH (1) | PH12021550449A1 (es) |
| SG (1) | SG11202101687TA (es) |
| TW (1) | TWI714231B (es) |
| UA (1) | UA124917C2 (es) |
| WO (1) | WO2020051058A1 (es) |
| ZA (1) | ZA202100700B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI750685B (zh) * | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| TWI764467B (zh) | 2019-12-24 | 2022-05-11 | 大陸商南京明德新藥研發有限公司 | 具有khk抑制作用的化合物 |
| CN111423420A (zh) * | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| JP2024512646A (ja) | 2021-03-29 | 2024-03-19 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｈｋ阻害剤 |
| WO2023151473A1 (zh) * | 2022-02-09 | 2023-08-17 | 上海研健新药研发有限公司 | 一种khk抑制剂，其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8030304B2 (en) * | 2006-09-20 | 2011-10-04 | Eli Lilly And Company | Thiazole pyrazolopyrimidines CRF1 receptor antagonists |
| AR099937A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| HUE045340T2 (hu) * | 2014-05-15 | 2019-12-30 | Array Biopharma Inc | 1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor |
| SG11201804363UA (en) | 2015-12-29 | 2018-07-30 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
-
2019
- 2019-08-23 TW TW108130153A patent/TWI714231B/zh active
- 2019-08-27 AR ARP190102434A patent/AR117640A1/es unknown
- 2019-08-29 KR KR1020217006473A patent/KR102365535B1/ko active IP Right Grant
- 2019-08-29 CN CN201980057907.2A patent/CN112601525B/zh active Active
- 2019-08-29 IL IL280598A patent/IL280598B2/en unknown
- 2019-08-29 UA UAA202100674A patent/UA124917C2/uk unknown
- 2019-08-29 MX MX2021002472A patent/MX2021002472A/es unknown
- 2019-08-29 WO PCT/US2019/048788 patent/WO2020051058A1/en unknown
- 2019-08-29 EA EA202190302A patent/EA202190302A1/ru unknown
- 2019-08-29 MA MA053547A patent/MA53547A/fr unknown
- 2019-08-29 BR BR112021001881-6A patent/BR112021001881A2/pt unknown
- 2019-08-29 PE PE2021000355A patent/PE20211595A1/es unknown
- 2019-08-29 US US16/555,075 patent/US10781212B2/en active Active
- 2019-08-29 EP EP19769621.4A patent/EP3846809B1/en active Active
- 2019-08-29 JO JOP/2021/0039A patent/JOP20210039A1/ar unknown
- 2019-08-29 JP JP2020537626A patent/JP6813720B1/ja active Active
- 2019-08-29 AU AU2019334877A patent/AU2019334877B2/en active Active
- 2019-08-29 CA CA3111725A patent/CA3111725C/en active Active
- 2019-08-29 CR CR20210085A patent/CR20210085A/es unknown
- 2019-08-29 SG SG11202101687TA patent/SG11202101687TA/en unknown
-
2021
- 2021-02-01 ZA ZA2021/00700A patent/ZA202100700B/en unknown
- 2021-02-16 DO DO2021000027A patent/DOP2021000027A/es unknown
- 2021-03-01 CO CONC2021/0002768A patent/CO2021002768A2/es unknown
- 2021-03-02 PH PH12021550449A patent/PH12021550449A1/en unknown
- 2021-03-03 CL CL2021000528A patent/CL2021000528A1/es unknown
- 2021-03-03 EC ECSENADI202115267A patent/ECSP21015267A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117640A1 (es) | Compuestos de 2,6-diaminopiridina como inhibidores de khk | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| CL2007001873A1 (es) | Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| EA201690035A1 (ru) | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| PE20080069A1 (es) | Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40) | |
| ECSP10010266A (es) | Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo[b,e]oxepina | |
| DK2358717T3 (da) | Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EA200971041A1 (ru) | Новые пептидные ингибиторы репликации вируса гепатита с | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| PE20121820A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| ME02015B (me) | Farmaceutski preparati sa (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi- 4-metilfenil]-1-tio-D-glucitolom i sekretagogom insulina | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| SI3031799T1 (en) | Aromatic compound | |
| ATE539743T1 (de) | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan | |
| PE20041039A1 (es) | Derivados de pirazol como moduladores de ppar | |
| CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| CO2021016870A2 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| HRP20180993T1 (hr) | Supstituirani natrij-1h-pirazol-5-olat | |
| NO20093039L (no) | Indolizineddiksyrederivater som CRTH2 antagonister | |
| AR063095A1 (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina |